Stockholders’ equity (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
Stockholders’ equity (Details Narrative) - USD ($)	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Sep. 29, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, share authorized		300,000,000	300,000,000
Preferred stock, share authorized		10,000,000	10,000,000
Common stock, par value		$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, par value		$ 0.0001	$ 0.0001
Stock-compensation expense		$ 1,441,823
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares granted		6,000,000
Vest over shares period description		The shares vest over a 4-year period from the issuance date.
Exchanged number of restricted shares issued	2,000,000	6,000,000
Unvested number of share issued	1,500,000	4,500,000
Stock-compensation expense		$ 1,240,000	$ 0
Fair value of restricted stock vested		$ 930,024
Restricted Stock Units (RSUs) [Member] \| Chief Executive Officer [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vest over shares period description	The shares vest over a 2-year period from the issuance date.
Unvested number of share issued	2,000,000
Restricted Stock Units (RSUs) [Member] \| Consultants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Weighted average remaining contractual period		3 years 9 months
Shares granted		729,168
Unvested number of share issued		729,168
Stock-compensation expense		$ 201,823
Fair value of restricted stock vested		291,917
Shares granted		$ 295,834
Outstanding shares not vested		258,334
Award vesting rights description		The stock awards vest over 48-month period from the grant date.
Accelerated vesting, number		470,834
Unrecognized stock-based compensation expense related to unvested restricted stock awards		$ 276,095
Restricted Stock Units (RSUs) [Member] \| Vendor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding shares not vested		175,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding and exercisable warrants to purchase		8,766,294
Weighted average exercise price		$ 1.52
Weighted average remaining contractual period		1 year 10 months 9 days
2025 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent		15.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum		4.00%
Options, outstanding		0

Palomino Laboratories Inc. 10-K